Regeneron Pharmaceuticals
-$2.1B
Net Activity
Institutions Holding
1403
Popularity Rank
#251
Avg Weight
0.24%
Total Value
$69.7B
1403 institutions currently hold REGN, with 686 net buyers and 576 net sellers this quarter.
Institutional Moves (Q1 2026)
Neutral
Based on recent trading activity
Net Selling Institutions
576
Net Buying Institutions
686
Top 5 by Value
Across its top 20 institutional holders, REGN's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 5/100, avg. turnover score 20/100).
+$43.2B
Total Buy Value
$26.2B
Total Sell Value
686
Net Buyers
576
Net Sellers
REGN: Neutral – Mixed Institutional Flows, Sparse Insider Action
Signal Basis
Institutional net value dropped $2.14B, yet 686 funds added versus 576 cut; insider activity shows a single $130K sale by a director with zero buying in 90 days. The opposing signals cancel out, leaving a neutral stance.
Confirmation
A quarter of clear institutional net accumulation or a cluster of insider buys would shift the verdict to bullish.
Invalidation Risk
Accelerated institutional net selling or a wave of insider sales would turn the verdict bearish.
The above is AI-generated from public regulatory filings and summarizes historical data only. It is not investment advice and should not be used as the basis for any buy or sell decision.
REGN does not currently show a 13F-and-insider convergence signal — its insider confidence score is 0/100, below the threshold this product uses to flag combined buying pressure.
13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.
0
unique buyers
—
buy value
12-Month Buy/Sell Activity
| Action | Insider | Date | Value |
|---|---|---|---|
| Sell | Arthur F Ryan | 2026-07-02 | $130K |
| Sell | Arthur F Ryan | 2026-03-02 | $16K |
| Sell | Arthur F Ryan | 2026-03-02 | $2K |
| Sell | Arthur F Ryan | 2026-03-02 | $6K |
| Sell | Arthur F Ryan | 2026-03-02 | $9K |
| Sell | Arthur F Ryan | 2026-03-02 | $2K |
| Sell | Arthur F Ryan | 2026-03-02 | $8K |
| Sell | Arthur F Ryan | 2026-03-02 | $2K |
1
Filings (90d)
$250K
Total Est. Value
400 shares
Planned Shares
| Filer | Filing Date | Est. Value |
|---|---|---|
| Arthur F. Ryan | 2026-07-02 | $250K |
Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。
No Schedule 13D/13G filings for this ticker
1
Filings (14d)
Regeneron announced that its second-quarter 2026 financial results will include a $127 million pre-tax charge for acquired in-process research and development (IPR&D) costs from collaboration and licensing agreements. This charge is expected to reduce both GAAP and non-GAAP earnings per diluted share by about $1.00. The results are preliminary and subject to final adjustment after closing procedures.
View Full Filing (SEC EDGAR)75886F107, 75886F907, 75886F957, 75886f107
Other stocks in the same GICS sector
Institutions Holding
4,603
Total reported value
$438.8B
1269 institutions currently hold both REGN and this stock
Institutions Holding
4,337
Total reported value
$730.5B
1281 institutions currently hold both REGN and this stock
Institutions Holding
4,024
Total reported value
$283.9B
1237 institutions currently hold both REGN and this stock
The most-added stocks by 13F institutions this quarter
Institutions Holding
6,150
Total reported value
$2.1T
3245 13F institutions increased their position this quarter
Institutions Holding
5,957
Total reported value
$1.5T
3028 13F institutions increased their position this quarter
Institutions Holding
5,764
Total reported value
$3.0T
2743 13F institutions increased their position this quarter